Loading data for NMRA — first visit, this takes a few seconds.

Neumora Therapeutics, Inc. (NMRA)

NasdaqGS: NMRA · Real-Time Price · USD

1.31

-0.04 (-2.96%)

At close: Sep 11, 2026, 8:00 PM

1.06

+1.92%

After-hours: 7:30 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	0.97
Market Cap	195M
Revenue (ttm)	n/a
Net Income (ttm)	-213M
	2.74
	-1.23
	n/a
	-1.55
P/B (ttm)	4.37
P/S (ttm)	0.00
Earnings Date	Nov 5, 2026

Ask	1.68
Volume	546,960
Avg. Volume (20D)	1,896,187
Open	1.35
Previous Close	1.35
Day's Range	1.29 - 1.36
52-Week Range	0.83 - 3.65
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About NMRA

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 14, 2023

Employees 63

Stock Exchange NasdaqGS

Ticker Symbol NMRA

Website https://www.neumoratx.com

Full Company Profile

Financial Performance

In 2025, Neumora Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -236.93M, a decrease of -2.81%.

Financial Statements

Earnings Surprise

Neumora Therapeutics has released their quarterly earnings on Aug 14, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.23 exceeds estimates by 0.01, with 30.30% YoY growth.

Next Earnings Release

Neumora Therapeutics, Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade

Why Price Moved

News

2 months ago · Simply Wall St.

Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation

Neumora Therapeutics is back in focus after analysts cut their fair value estimate from US$8.91 to US$6.53 per share, a reduction of about 27% that resets expectations around the stock. Much of this s...

2 months ago · Insider Monkey

Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is among the best get rich quick stocks to buy right now. On June 18, Mizuho lowered the price target on Neumora Therapeutics, Inc. (NASDAQ:NMRA) to $4, down f...

2 months ago · Insider Monkey

LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential

We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. LB Pharmaceuticals Inc. (NASDAQ:LBRX) is one of the best up and coming stocks on our list. TheFly reported on ...

2 months ago · Insider Monkey

Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main near-term catalyst is navacaprant, an experimental depression treatment ...

2 months ago · Clinical Trials Arena

Three pivotal MDD trial failures for Neumora lead to staffing cuts

The KOASTAL 2 and KOASTAL 3 trials also failed to meet their endpoints, with Neumora now culling development of the MDD candidate

Page 1 of 2

Neumora Therapeutics, Inc. (NMRA)